Sustained-release of FGF-2 from a Hybrid Hydrogel of Heparin-poloxamer and Decellular Matrix Promotes the Neuroprotective Effects of Proteins After Spinal Injury
Overview
Authors
Affiliations
Introduction: The short lifetime of protein-based therapies has largely limited their therapeutic efficacy in injured nervous post-spinal cord injury (post-SCI).
Methods: In this study, an affinity-based hydrogel delivery system provided sustained-release of proteins, thereby extending the efficacy of such therapies. The affinity-based hydrogel was constructed using a novel polymer, heparin-poloxamer (HP), as a temperature-sensitive bulk matrix and decellular spinal cord extracellular matrix (dscECM) as an affinity depot of drug. By tuning the concentration of HP in formulation, the cold ternary fibroblast growth factor-2 (FGF2)-dscECM-HP solution could rapidly gelatinize into a hydrogel at body temperature. Due to the strong affinity for FGF2, hybrid FGF2-dscECM-HP hydrogel enabled sustained-release of encapsulated FGF2 over an extended period in vitro.
Results: Compared to free FGF2, it was observed that both neuron functions and tissue morphology after SCI were clearly recovered in rats treated with FGF2-dscECM-HP hydrogel. Moreover, the expression of neurofilament protein and the density of axons were increased after treatment with hybrid FGF2-dscECM-HP. In addition, the neuroprotective effects of FGF2-dscECM-HP were related to inhibition of chronic endoplasmic reticulum stress-induced apoptosis.
Conclusion: The results revealed that a hybrid hydrogel system may be a potential carrier to deliver macromolecular proteins to the injured site and enhance the therapeutic effects of proteins.
Zhou Z, Bu Z, Wang S, Yu J, Liu W, Huang J J Nanobiotechnology. 2024; 22(1):438.
PMID: 39061089 PMC: 11282598. DOI: 10.1186/s12951-024-02718-8.
Long-Acting Ocular Injectables: Are We Looking In The Right Direction?.
Dang M, Shoichet M Adv Sci (Weinh). 2023; 11(8):e2306463.
PMID: 38018313 PMC: 10885661. DOI: 10.1002/advs.202306463.
Yue W, Shen J Pharmaceuticals (Basel). 2023; 16(6).
PMID: 37375758 PMC: 10302941. DOI: 10.3390/ph16060810.
Du P, Diao L, Lu Y, Liu C, Li J, Chen Y Heliyon. 2023; 9(3):e13554.
PMID: 36851964 PMC: 9958445. DOI: 10.1016/j.heliyon.2023.e13554.
Peng H, Liu Y, Xiao F, Zhang L, Li W, Wang B Front Bioeng Biotechnol. 2023; 11:1111882.
PMID: 36741755 PMC: 9889880. DOI: 10.3389/fbioe.2023.1111882.